SK Biopharmaceuticals Holds U.S. POA Meeting: "Preparing for Multi-Product Era"
Review of Second-Half Performance and Concrete On-Site Action Strategies
SK Biopharmaceuticals' U.S. subsidiary, SK Life Science, announced on October 2 that it held its "2026 Plan of Action (POA)" meeting in Chicago, Illinois, from September 29 to October 1 (local time). The company aimed to strengthen on-site execution and commercial capabilities for continued growth of its U.S. business.
The POA meeting is an event where sales personnel from U.S. pharmaceutical and biotech companies gather to review business performance, evaluate market conditions, and share future action strategies.
Donghoon Lee, CEO of SK Biopharm, is giving a presentation at the '2026 Plan of Action' meeting. SK Biopharm
View original imageApproximately 160 participants, mainly from the U.S. sales team, attended the event to review first-half results and shifts in the market, and to discuss action strategies for continuing the growth momentum of cenobamate in the second half. They also exchanged ideas on ways to expand and leverage the commercial capabilities established in the U.S. to prepare for new product launches and portfolio expansion in the future.
SK Biopharmaceuticals' strategy is to build a global epilepsy franchise by acquiring new products and maximizing utilization of its current sales organization, based on the local commercial capabilities accumulated through cenobamate in areas such as sales, marketing, and market access. The company also plans to expand cenobamate's formulations—including oral suspension—and to broaden its indications and prescriptions to include pediatric and adolescent patients as well as primary generalized tonic-clonic (PGTC) seizures.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Donghoon Lee, CEO of SK Biopharmaceuticals, said, "Headquarters and our U.S. operations will move even faster and execute more fiercely as ‘One Team,’ continuing the growth of cenobamate, while also turning the era of multiple products into real achievements."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.